Developing a Universal Flu Vaccine

The video discusses the challenges of developing a long-term flu vaccine due to the virus's rapid evolution. Scientists in Ghent, Belgium, are working on a vaccine targeting a stable protein in the flu virus, which could provide consistent protection. This approach could simplify production and reduce costs. However, large-scale testing is needed to prove its effectiveness, which poses financial challenges. Despite differing opinions, the team remains optimistic about their method's potential.

What is the main challenge in developing a flu vaccine each year?

• The flu virus evolves rapidly, making previous vaccines ineffective.

• The flu virus is resistant to all known vaccines.

• The flu virus only affects certain regions.

• There is a shortage of materials to produce vaccines.

What unique approach is Professor Saelens' team using to develop a flu vaccine?

• Focusing on the symptoms rather than the virus itself.

• Developing a vaccine that changes every year.

• Using a combination of existing vaccines.

• Targeting a stable protein in the flu virus that does not mutate.

Why is the new vaccine production process considered more cost-effective?

• It uses fewer resources and is quicker to produce.

• It targets a stable protein, eliminating the need for annual changes.

• It requires less testing and approval.

• It is produced in larger quantities.

What is a concern some scientists have about the new vaccine approach?

• The vaccine requires a long time to develop.

• Targeting a small protein may not be effective.

• The vaccine is too expensive to produce.

• The vaccine is only effective in certain climates.

What is necessary to prove the effectiveness of the new flu vaccine?

• Approval from a single health organization.

• Immediate distribution to the public.

• Conducting large-scale tests over several flu seasons.

• Testing on a small group of individuals.